Jacques Dubois
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacques Dubois has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Claude St-Pierre
Novabyss Inc., Centre Universitaire de Santé de l’Estrie, 614 rue Bowen Sud, Sherbrooke, Québec J1G 2E9, Canada
1 shared publication
Latest Publications
- Open Access
- 1 April 2000
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 45 (90003) , 41
Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
The comparative in vitro potency and post-antibiotic effect (PAE) of gemifloxacin (SB-265805), moxifloxacin, trovafloxacin, grepafloxacin, levofloxacin, ofloxacin, ciprofloxacin, azithromycin, clarithromycin, erythromycin and rifampicin were evaluated against Legionella pneumophila serogroups 1–9 and 12 (n = 204) and other Legionella spp. (n = 34). MICs were determined by standard two-fold agar dilution. PAE was determined by exposing the isolates to the test agents at 4 × MIC for 1 h. Trovafloxacin was the most potent agent overall (MIC range ≤0.004–0.016 mg/L, MIC90 ≤0.008 mg/L). Of the other quinolones tested, gemifloxacin, moxifloxacin, grepafloxacin and levofloxacin were more potent (MIC90 0.016 mg/L) against L. pneumophila than ciprofloxacin and ofloxacin (MIC90 0.03 mg/L). Against Legionella spp., the test quinolones were more potent (MIC range ≤0.004–0.06 mg/L) than either erythromycin or azithromycin (MIC90 0.5 and 0.25 mg/L, respectively). Gemifloxacin had the longest PAE (4.65 h) of the agents tested against erythromycin-resistant L. pneumophila. Of the quinolones, only gemifloxacin, grepafloxacin, levofloxacin and ofloxacin had PAEs of >3 h against erythromycin-resistant Legionella spp. Azithromycin, erythromycin and clarithromycin had PAEs of 3 h, and only rifampicin, ofloxacin, gemifloxacin and erythromycin had PAEs of >2 h against erythromycin-susceptible Legionella spp. The superior potency of gemifloxacin compared with erythromycin indicates that it may be of use in the treatment of legionellosis. The significant PAE described here, combined with favourable pharmacokinetics, supports once-daily dosing for gemifloxacin in the treatment of legionella infections.
- 1 April 2000
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 45 (90003) , 41
Open AccessComparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
The comparative in vitro potency and post-antibiotic effect (PAE) of gemifloxacin (SB-265805), moxifloxacin, trovafloxacin, grepafloxacin, levofloxacin, ofloxacin, ciprofloxacin, azithromycin, clarithromycin, erythromycin and rifampicin were evaluated against Legionella pneumophila serogroups 1–9 and 12 (n = 204) and other Legionella spp. (n = 34). MICs were determined by standard two-fold agar dilution. PAE was determined by exposing the isolates to the test agents at 4 × MIC for 1 h. Trovafloxacin was the most potent agent overall (MIC range ≤0.004–0.016 mg/L, MIC90 ≤0.008 mg/L). Of the other quinolones tested, gemifloxacin, moxifloxacin, grepafloxacin and levofloxacin were more potent (MIC90 0.016 mg/L) against L. pneumophila than ciprofloxacin and ofloxacin (MIC90 0.03 mg/L). Against Legionella spp., the test quinolones were more potent (MIC range ≤0.004–0.06 mg/L) than either erythromycin or azithromycin (MIC90 0.5 and 0.25 mg/L, respectively). Gemifloxacin had the longest PAE (4.65 h) of the agents tested against erythromycin-resistant L. pneumophila. Of the quinolones, only gemifloxacin, grepafloxacin, levofloxacin and ofloxacin had PAEs of >3 h against erythromycin-resistant Legionella spp. Azithromycin, erythromycin and clarithromycin had PAEs of 3 h, and only rifampicin, ofloxacin, gemifloxacin and erythromycin had PAEs of >2 h against erythromycin-susceptible Legionella spp. The superior potency of gemifloxacin compared with erythromycin indicates that it may be of use in the treatment of legionellosis. The significant PAE described here, combined with favourable pharmacokinetics, supports once-daily dosing for gemifloxacin in the treatment of legionella infections.